Biomaterials Global Market Report 2024

The biomaterials refer to manmade substances that can be utilized to support tissues or structures in the body. These are natural or synthetic materials that are used in medical applications to support, enhance, or replace damaged tissue or a biological function.

The main types of biomaterials are metallic biomaterial, polymeric biomaterials, natural biomaterials and ceramics. The metallic biomaterials are stainless steels, titanium alloys, and cobalt alloys used to provide internal support to biological tissues. The metallic biomaterials are manmade systems that are utilized in joint replacements, dental implants, orthopedic fixations, and stents to offer internal support to biological tissues. Biomaterials have a wide application in cardiovascular, orthopedic, ophthalmology, dental, plastic surgery, wound healing, tissue engineering and neurological/central nervous system and are used in hospitals and clinics, ambulatory surgical centers and other end users.

The biomaterials market research report is one of a series of new reports that provides biomaterials market statistics, including biomaterials industry global market size, regional shares, competitors with a biomaterials market share, detailed biomaterials market segments, market trends and opportunities, and any further data you may need to thrive in the biomaterials industry. This biomaterials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biomaterials market size has grown rapidly in recent years. It will grow from $118.51 billion in 2023 to $136.08 billion in 2024 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to growing aging population, adoption of biomaterials in orthopedic and dental applications, increasing awareness of environmental sustainability, increased prevalence of chronic conditions medicine, increased demand for medical implants.

The biomaterials market size is expected to see rapid growth in the next few years. It will grow to $230 billion in 2028 at a compound annual growth rate (CAGR) of 14.0%. The growth in the forecast period can be attributed to shifting consumer preferences, surge in demand for biomaterials in 3d printing and additive manufacturing, expansion of the biodegradable and bioresorbable biomaterials segment, adoption of biomaterials in drug delivery systems for personalized medicine, increasing use of biomaterials in wound care and tissue regeneration. Major trends in the forecast period include development of smart biomaterials with responsive and adaptive properties, integration of nanotechnology for enhanced functionality, emphasis on precision medicine leading to customized biomaterial solutions, exploration of marine and plant-derived biomaterial sources, collaboration between biomaterial companies and healthcare institutions for innovative applications.

The rising incidence of cardiovascular diseases is driving the growth of the biomaterials market. Cardiovascular disorders are caused by high blood pressure, smoking, high cholesterol, inactivity, and other factors. The increase in the prevalence of cardiovascular disorders is mainly due to noncontagious diseases such as diabetes, chronic respiratory illness, coronary artery disease (CAD) and heart attacks due to hypertension. Biomaterials such as heart valves, cardiopulmonary bypass systems, stents, vascular grafts, complete artificial hearts, and pacemakers are used as a healing mechanism for damaged and diseased heart tissue. For instance, in May 2023, according to the Centers for Disease Control and Prevention, a US-based public agency, coronary artery disease (CAD) was responsible for killing 375,476 people in 2021, and about 1 in 20 adults age 20 and older had CAD. In addition, about 2 in 10 deaths from CAD happen to adults less than 65 years old. Therefore, the rising incidence of cardiovascular diseases will increase the demand for biomaterials market.

The increasing healthcare spending will propel the growth of the biomaterials market. Healthcare spending refers to the total financial resources allocated for medical services, treatments, and healthcare infrastructure within a given period, typically on a national or institutional level. Healthcare spending is used in biomaterials for research and development, product development, procurement and adoption, and regulatory compliance. For instance, in September 2022, according to MedTech Europe, a Belgium-based European trade association representing the medical technology industries, in Europe, on average, approximately 11% of gross domestic product (GDP) is allocated to healthcare. Out of this, about 7.6% is attributed to medical technologies. The spending on medical technology across European countries ranges from around 5% to 12% of the total healthcare expenditure. The per capita expenditure on medical technology in Europe stands at approximately $346.08 (€284). Therefore, increasing healthcare spending will contribute to the growth of the biomaterials market.

Strategic partnerships are a key trend gaining popularity in the biomaterials market. Key companies are focusing on partnerships to develop new implants and combination devices based on biomaterials by leveraging each other’s expertise, technology, and resources. These partnerships are also focused on enhancing the adoption of biomaterials. Such partnerships enable companies to gain a competitive edge in the market and increase revenue. For instance, in September 2021, Cambium Biomaterials, a US-based producer of ultra-high-performance biomaterials, partnered with Ginkgo Bioworks Inc., a US-based biological engineering company, to accelerate industrial adoption of high-performance biomaterials. The collaboration will use Ginkgo's Codebase and high-throughput facilities to speed Cambium's discovery, development, manufacture, and commercialization of biomaterials that provide superior performance and sustainability across a variety of industries.

Major companies operating in the biomaterials market focus on technological advancements, such as the designed enzymatic biomaterials (DEB) technology platform, to deliver sustainable biopolymers and gain a competitive advantage. The enzymatic biomaterials (DEB) technology platform involves the use of enzymes to design and modify materials for various applications, including drug delivery, tissue engineering, and diagnostics. For instance, in June 2023, International Flavors & Fragrances Inc., a US-based producer of flavors, fragrances, and cosmetic actives, launched the enzymatic biomaterials technology platform for the development of biobased materials at scale. Designed to deliver meaningful sustainability benefits with performance comparable to or superior to fossil-based materials, DEB technology helps to address growing preferences for environmentally friendly, high-performance biopolymers. The technology platform allows producers to fulfill regulatory changes and increasing consumer demand by replacing traditional fossil-based synthetic polymers.

In January 2021, Evonik Industries AG, a German specialty chemicals company acquired the LACTEL business of biodegradable polymers from DURECT Corporation for $15 million. With this acquisition, Evonik aims to expand in fast-growing markets such as biomaterials for tissue engineering, advanced drug delivery, and the 3D printing of implantable medical devices. DURECT Corporation is a US-based specialty pharmaceutical company.

Major companies operating in the in the biomaterials market report are Carpenter Technology Corporation, Corbion N V, Evonik Industries AG, Heraeus Medical Components LLC, Berkeley Advanced Biomaterials Inc., Zimmer Biomet Holdings Inc., DSM Biomedical BV, PolyNovo Limited, Baxter International Inc., Stryker Corporation, Collagen Solutions plc, Invibio Ltd., Aap Implantate AG, Cam Bioceramics BV, CeramTec GmbH, CoorsTek Medical LLC, CryoLife Inc., Cerapedics Inc., Surmodics Inc., Secant Group LLC, GELITA AG, Quattroflow GmbH, Kyocera Corporation, Wright Medical Group NV, KLS Martin Group GmbH & Co KG, Meccellis Biotechnology Co Ltd., Bio-on SpA, Coloplast A/S, Collagen Matrix Inc., IntrinsiQ Materials Inc., PolyActiva Pty Ltd

North America was the largest region in the biomaterials market in 2023. The regions covered in the biomaterials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the biomaterials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The biomaterials market consists of sales of metals, polymers, and composites. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.